KKR Genetic Disorder L.P. - May 12, 2025 SCHEDULE 13D/A Report for BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share (BBIO)

Filing Manager
KKR Genetic Disorder L.P.
Reporting Manager
KKR Genetic Disorder L.P.
Security
BridgeBio Pharma, Inc. Common Stock, par value $0.001 per share
Symbol
BBIO
Shares outstanding
189M shares
Disclosed Ownership
13.3M shares
Ownership
7%
Form type
SCHEDULE 13D/A
Date filed
5/14/2025, 05:52 PM
Date of event
May 12, 2025
Previous filing
Mar 7, 2025
SEC
View on sec.gov

Reporting Managers (9)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
KKR Genetic Disorder L.P. 7% 13.3M 13.3M 0 /s/ Christopher Lee Christopher Lee, Assistant Secretary, KKR Genetic Disorder GP LLC, its general partner 0001780408
KKR Genetic Disorder GP LLC 7% 13.3M 13.3M 0 /s/ Christopher Lee Christopher Lee, Assistant Secretary
KKR Group Partnership L.P. 7% 13.3M 13.3M 0 /s/ Christopher Lee Christopher Lee, Secretary, KKR Group Holdings Corp., its general partner
KKR Group Holdings Corp. 7% 13.3M 13.3M 0 /s/ Christopher Lee Christopher Lee, Secretary
KKR Group Co. Inc. 7% 13.3M 13.3M 0 /s/ Christopher Lee Christopher Lee, Secretary
KKR & Co. Inc. 7% 13.3M 13.3M 0 /s/ Christopher Lee Christopher Lee, Secretary
KKR Management LLP 7% 13.3M 13.3M 0 /s/ Christopher Lee Christopher Lee, Assistant Secretary
Henry R. Kravis 7% 13.3M 0 13.3M /s/ Christopher Lee Christopher Lee, Attorney-in-fact
George R. Roberts 7% 13.3M 0 13.3M /s/ Christopher Lee Christopher Lee, Attorney-in-fact